<DOC>
	<DOCNO>NCT02832297</DOCNO>
	<brief_summary>In 12-month multi-center prospective , site-randomized , two-arm trial , approximately 265 biologic-naïve subject RA candidate treatment intensification due inadequate response MTX monotherapy enrol 60 study site .</brief_summary>
	<brief_title>Prospective Outcomes Study : Vectra® DA Guided Care Compared Usual Care</brief_title>
	<detailed_description>To determine whether strategy Vectra DA guide care ( Arm A ) , compare usual care ( Arm B ) , achieve non-inferior clinical outcome reduce cost treatment patient active RA inadequate response MTX monotherapy .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects eligible participate study meet follow criterion : 1 . Willing able sign ICF 2 . Age 18 80 year enrollment 3 . Meets 2010 ACR/EULAR criterion and/or 1987 criterion RA , determine boardcertified rheumatologist ≥3 month prior enrollment 4 . Received uninterrupted treatment weekly MTX begin ≥3 month prior enrollment , stable dose ≥15 mg per week least 4 week prior enrollment . A history therapy split dose oral MTX parenteral MTX acceptable weekly MTX dose always ≤20 mg/week 3 month prior enrollment . 5 . CDAI &gt; 10 assessed Investigator screen 6 . At least 3 swollen joint ( SJC ≥3 ) 3 tender joint ( TJC ≥3 ) 28 joint assessed Investigator screen 7 . Must eligible treatment intensification nonbiologic biologic DMARDs 8 . Documented evidence seropositivity ( RF and/or antiCCP antibody ) . Seronegative subject allow erosive disease attributable RA document Xrays . Subjects ineligible participate study meet follow criterion : 1 . Use nonbiologic DMARD MTX within 3 month prior enrollment 2 . MTX administer SQ oral split dose &gt; 20 mg/week time 3 month prior enrollment 3 . Two DMARDs use combination ( i.e. , concomitantly ) , include limited : MTX , HCQ , SSZ , LEF , cyclosporine , azathioprine , gold penicillamine time prior enrollment 4 . Biologic DMARD JAKi use time prior enrollment 5 . Any contraindication use MTX , HCQ , LEF biologic DMARDs 6 . Opiate use 2 week prior enrollment 7 . Oral corticosteroid month prior enrollment dosage &gt; 10 mg/day prednisone ( equivalent ) nonstable dose ≤10 mg/day prednisone ( equivalent ) 8 . MTX intolerance prior enrollment limit use 9 . Inflammatory joint disease ( RA ) systemic autoimmune disorder . ( Osteoarthritis basis exclusion . ) 10 . Primary secondary immunodeficiency 11 . Active infection ( exclude fungal infection nail bed ) ; acute chronic infection require hospitalization treatment parenteral systemic antibiotic within one month enrollment treatment oral antibiotic within 2 week enrollment 12 . IA , intravenous IM corticosteroid month prior enrollment 13 . Initiation nonstable dosing NSAIDs within 2 week prior enrollment 14 . Vectra DA test within 3 month prior enrollment 15 . Live vaccine within 90 day enrollment 16 . Active substance abuse psychiatric illness likely interfere protocol conduct 17 . History severe allergic anaphylactic reaction monoclonal antibody therapy 18 . Known infection HIV ( HIV test requirement trial entry ) ; past current history hepatitis B virus hepatitis C virus infection 19 . History malignancy within past five year evidence persistent malignancy , except fully excise basal cell squamous cell carcinoma skin , cervical carcinoma situ treat excised curative procedure 20 . Pregnancy inadequate contraception woman childbearing potential 21 . Breast feed lactate 22 . Medical , psychiatric , cognitive condition , opinion Investigator , may compromise ability subject understand study information , give informed consent , comply trial protocol , complete study 23 . Presently enrol another clinical trial 24 . Vectra DA score screen outside applicable range require subject enrollment Note : Screening TB required subject participate study . If Investigator consider subject treatment biologic DMARD study , guideline TB screen need follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>